JP2008535848A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008535848A5 JP2008535848A5 JP2008505559A JP2008505559A JP2008535848A5 JP 2008535848 A5 JP2008535848 A5 JP 2008535848A5 JP 2008505559 A JP2008505559 A JP 2008505559A JP 2008505559 A JP2008505559 A JP 2008505559A JP 2008535848 A5 JP2008535848 A5 JP 2008535848A5
- Authority
- JP
- Japan
- Prior art keywords
- salt form
- crystalline salt
- crystalline
- composition
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical group 0.000 claims 24
- 239000000203 mixture Substances 0.000 claims 7
- 238000000634 powder X-ray diffraction Methods 0.000 claims 6
- UUCJNYSXZJNSLE-UHFFFAOYSA-N 2-oxo-1-propan-2-ylquinoline-3-carboxylic acid Chemical compound C1=CC=C2C=C(C(O)=O)C(=O)N(C(C)C)C2=C1 UUCJNYSXZJNSLE-UHFFFAOYSA-N 0.000 claims 5
- 238000000113 differential scanning calorimetry Methods 0.000 claims 5
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 3
- 206010010774 Constipation Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 239000000969 carrier Substances 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- -1 methanesulfonyl-methyl-amino Chemical group 0.000 claims 2
- 239000011541 reaction mixture Substances 0.000 claims 2
- 239000000725 suspension Substances 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000006549 dyspepsia Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 230000003483 hypokinetic effect Effects 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 230000004899 motility Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 208000018556 stomach disease Diseases 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66878005P | 2005-04-06 | 2005-04-06 | |
| US60/668,780 | 2005-04-06 | ||
| PCT/US2006/012978 WO2006108127A2 (en) | 2005-04-06 | 2006-04-05 | Crystalline form of a quinolinone-carboxamide compound |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012113464A Division JP2012153725A (ja) | 2005-04-06 | 2012-05-17 | キノリン−カルボキサミド化合物の結晶形態物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008535848A JP2008535848A (ja) | 2008-09-04 |
| JP2008535848A5 true JP2008535848A5 (enExample) | 2009-05-07 |
| JP5230407B2 JP5230407B2 (ja) | 2013-07-10 |
Family
ID=37074104
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008505559A Active JP5230407B2 (ja) | 2005-04-06 | 2006-04-05 | キノリン−カルボキサミド化合物の結晶形態物 |
| JP2012113464A Withdrawn JP2012153725A (ja) | 2005-04-06 | 2012-05-17 | キノリン−カルボキサミド化合物の結晶形態物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012113464A Withdrawn JP2012153725A (ja) | 2005-04-06 | 2012-05-17 | キノリン−カルボキサミド化合物の結晶形態物 |
Country Status (29)
| Country | Link |
|---|---|
| US (4) | US7728004B2 (enExample) |
| EP (1) | EP1874766B1 (enExample) |
| JP (2) | JP5230407B2 (enExample) |
| KR (1) | KR101322873B1 (enExample) |
| CN (1) | CN101151264B (enExample) |
| AR (2) | AR053208A1 (enExample) |
| AT (1) | ATE479682T1 (enExample) |
| AU (1) | AU2006232129B2 (enExample) |
| BR (1) | BRPI0610657A2 (enExample) |
| CA (1) | CA2603654C (enExample) |
| CY (1) | CY1111275T1 (enExample) |
| DE (1) | DE602006016586D1 (enExample) |
| DK (1) | DK1874766T3 (enExample) |
| EA (1) | EA012115B1 (enExample) |
| ES (1) | ES2350495T3 (enExample) |
| HR (1) | HRP20100629T1 (enExample) |
| IL (1) | IL186023A (enExample) |
| MA (1) | MA29403B1 (enExample) |
| MX (1) | MX2007012438A (enExample) |
| MY (1) | MY151075A (enExample) |
| NO (1) | NO339699B1 (enExample) |
| NZ (1) | NZ561900A (enExample) |
| PE (1) | PE20061310A1 (enExample) |
| PL (1) | PL1874766T3 (enExample) |
| PT (1) | PT1874766E (enExample) |
| SI (1) | SI1874766T1 (enExample) |
| TW (1) | TWI377206B (enExample) |
| WO (1) | WO2006108127A2 (enExample) |
| ZA (1) | ZA200708071B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7063671B2 (en) * | 2002-06-21 | 2006-06-20 | Boston Scientific Scimed, Inc. | Electronically activated capture device |
| TWI351282B (en) * | 2004-04-07 | 2011-11-01 | Theravance Inc | Quinolinone-carboxamide compounds as 5-ht4 recepto |
| US7728006B2 (en) * | 2004-04-07 | 2010-06-01 | Theravance, Inc. | Quinolinone-carboxamide compounds as 5-HT4 receptor agonists |
| EP1807423B1 (en) | 2004-11-05 | 2009-05-20 | Theravance, Inc. | Quinolinone-carboxamide compounds |
| ES2332808T3 (es) * | 2004-11-05 | 2010-02-12 | Theravance, Inc. | Compuestos agonistas del receptor 5-ht4. |
| TWI377206B (en) * | 2005-04-06 | 2012-11-21 | Theravance Inc | Crystalline form of a quinolinone-carboxamide compound |
| ES2778846T3 (es) | 2005-11-08 | 2020-08-12 | Vertex Pharma | Moduladores heterocíclicos de transportadores de casete de unión a ATP |
| WO2008143916A2 (en) * | 2007-05-17 | 2008-11-27 | Theravance, Inc. | Prokinetic agent for bowel preparation |
| CH698729B1 (de) * | 2007-05-30 | 2009-10-15 | Cerbios Pharma Sa | Stabile, kristalline (6S)-N(5)-Methyl-5, 6,7,8-tetrahydrofolsäure. |
| KR20150063170A (ko) | 2007-12-07 | 2015-06-08 | 버텍스 파마슈티칼스 인코포레이티드 | 3-(6-(1-(2,2-디플루오로벤조[ｄ][1,3]디옥솔-5-일)사이클로프로판카복스아미도)-3-메틸피리딘-2-일)벤조산의 고체 형태 |
| US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
| JP2012523437A (ja) * | 2009-04-13 | 2012-10-04 | セラヴァンス， インコーポレーテッド | 認知障害の治療のための５−ｈｔ４受容体アゴニスト化合物 |
| CN102762572A (zh) | 2010-02-01 | 2012-10-31 | 诺瓦提斯公司 | 作为CRF-1受体拮抗剂的吡唑并[5,1b]*唑衍生物 |
| AR080056A1 (es) | 2010-02-01 | 2012-03-07 | Novartis Ag | Derivados de ciclohexil-amida como antagonistas de los receptores de crf |
| JP5748777B2 (ja) | 2010-02-02 | 2015-07-15 | ノバルティス アーゲー | Ｃｒｆ受容体アンタゴニストとしてのシクロヘキシルアミド誘導体 |
| BR112012026255A2 (pt) | 2010-04-07 | 2017-03-14 | Vertex Pharma | composições farmacêuticas de ácido 3-(6-(1-(2-,2-difluorbenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiridin-2-il)benzóico e administração das mesmas |
| DK2806859T3 (da) | 2012-01-25 | 2019-08-05 | Vertex Pharma | Formuleringer af 3-(6-(1-(2.2-difluorbenzo[d][1,3]dioxol-5-yl) cyclopropancarboxamido)-3-methylpyridin-2-yl)benzoesyre |
| DK3068392T5 (da) | 2013-11-12 | 2021-09-20 | Vertex Pharma | Fremgangsmåde til fremstilling af farmaceutiske sammensætninger til behandlingen af cftr-medierede sygdomme |
| EP3661518B1 (en) | 2017-07-31 | 2024-08-28 | Alfasigma S.p.A. | Methods of treating symptoms of gastroparesis using velusetrag |
| US10570127B1 (en) | 2018-11-05 | 2020-02-25 | Renexxion, Llc | Material and methods for the treatment of gastro-intestinal disorders |
| CA3263063A1 (en) | 2022-09-20 | 2024-03-28 | Alfasigma S.P.A. | VELUSETRAG INTENDED FOR USE IN THE TREATMENT OF CHRONIC INTESTINAL PSEUDO-OBSTRUCTION (CIPO) |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3122671B2 (ja) | 1990-05-23 | 2001-01-09 | 協和醗酵工業株式会社 | 複素環式化合物 |
| CA2097815C (en) | 1990-12-28 | 2001-04-17 | Fumio Suzuki | Quinoline derivative |
| EP0670319A4 (en) | 1992-11-20 | 1996-01-17 | Thaisho Pharmaceutical Co Ltd | HETEROCYCLIC COMPOUNDS. |
| JP3829879B2 (ja) | 1994-05-18 | 2006-10-04 | 大正製薬株式会社 | キノリンカルボン酸誘導体 |
| TW548103B (en) * | 1997-07-11 | 2003-08-21 | Janssen Pharmaceutica Nv | Bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives |
| US7105195B2 (en) * | 2003-07-25 | 2006-09-12 | General Mills, Inc. | Reduced trans fat product |
| CA2545092C (en) | 2003-11-24 | 2010-08-17 | Pfizer Inc. | Quinolonecarboxylic acid compounds having 5-ht4 receptor agonistic activity |
| TWI351282B (en) * | 2004-04-07 | 2011-11-01 | Theravance Inc | Quinolinone-carboxamide compounds as 5-ht4 recepto |
| US7728006B2 (en) | 2004-04-07 | 2010-06-01 | Theravance, Inc. | Quinolinone-carboxamide compounds as 5-HT4 receptor agonists |
| EP1807423B1 (en) | 2004-11-05 | 2009-05-20 | Theravance, Inc. | Quinolinone-carboxamide compounds |
| ES2332808T3 (es) | 2004-11-05 | 2010-02-12 | Theravance, Inc. | Compuestos agonistas del receptor 5-ht4. |
| WO2006088988A1 (en) | 2005-02-17 | 2006-08-24 | Theravance, Inc. | Crystalline form of an indazole-carboxamide compound |
| ES2523851T3 (es) | 2005-03-02 | 2014-12-02 | Theravance Biopharma R&D Ip, Llc | Compuestos de quinolinona como agonistas de los receptores 5-HT4 |
| TWI377206B (en) * | 2005-04-06 | 2012-11-21 | Theravance Inc | Crystalline form of a quinolinone-carboxamide compound |
-
2006
- 2006-03-27 TW TW095110607A patent/TWI377206B/zh not_active IP Right Cessation
- 2006-04-03 MY MYPI20061482 patent/MY151075A/en unknown
- 2006-04-03 PE PE2006000360A patent/PE20061310A1/es not_active Application Discontinuation
- 2006-04-05 HR HR20100629T patent/HRP20100629T1/hr unknown
- 2006-04-05 AT AT06740692T patent/ATE479682T1/de active
- 2006-04-05 JP JP2008505559A patent/JP5230407B2/ja active Active
- 2006-04-05 AU AU2006232129A patent/AU2006232129B2/en active Active
- 2006-04-05 ES ES06740692T patent/ES2350495T3/es active Active
- 2006-04-05 SI SI200630833T patent/SI1874766T1/sl unknown
- 2006-04-05 WO PCT/US2006/012978 patent/WO2006108127A2/en not_active Ceased
- 2006-04-05 DE DE602006016586T patent/DE602006016586D1/de active Active
- 2006-04-05 KR KR1020077025632A patent/KR101322873B1/ko active Active
- 2006-04-05 US US11/398,119 patent/US7728004B2/en active Active
- 2006-04-05 DK DK06740692.6T patent/DK1874766T3/da active
- 2006-04-05 CN CN2006800107676A patent/CN101151264B/zh active Active
- 2006-04-05 BR BRPI0610657-9A patent/BRPI0610657A2/pt not_active Application Discontinuation
- 2006-04-05 PT PT06740692T patent/PT1874766E/pt unknown
- 2006-04-05 CA CA2603654A patent/CA2603654C/en active Active
- 2006-04-05 MX MX2007012438A patent/MX2007012438A/es active IP Right Grant
- 2006-04-05 NZ NZ561900A patent/NZ561900A/en unknown
- 2006-04-05 EP EP06740692A patent/EP1874766B1/en active Active
- 2006-04-05 PL PL06740692T patent/PL1874766T3/pl unknown
- 2006-04-05 EA EA200702161A patent/EA012115B1/ru not_active IP Right Cessation
- 2006-04-06 AR ARP060101375A patent/AR053208A1/es not_active Application Discontinuation
-
2007
- 2007-09-18 IL IL186023A patent/IL186023A/en active IP Right Grant
- 2007-09-19 ZA ZA200708071A patent/ZA200708071B/xx unknown
- 2007-10-25 MA MA30317A patent/MA29403B1/fr unknown
- 2007-11-02 NO NO20075574A patent/NO339699B1/no not_active IP Right Cessation
-
2010
- 2010-04-13 US US12/759,080 patent/US8658671B2/en active Active
- 2010-11-25 CY CY20101101076T patent/CY1111275T1/el unknown
-
2012
- 2012-05-17 JP JP2012113464A patent/JP2012153725A/ja not_active Withdrawn
-
2014
- 2014-01-08 US US14/150,059 patent/US9126994B2/en active Active
-
2015
- 2015-08-03 US US14/816,237 patent/US9402840B2/en active Active
-
2017
- 2017-11-01 AR ARP170103029A patent/AR110019A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008535848A5 (enExample) | ||
| CA2603654A1 (en) | Crystalline hydrochloride salt of a quinolinone-carboxamide compound or a solvate thereof | |
| JP2010514807A5 (enExample) | ||
| TW201002682A (en) | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine | |
| CN1575287A (zh) | 乙酰替苯胺衍生物的α型或β型结晶 | |
| JP2018065876A (ja) | ニロチニブと選択された共結晶体を含有する多成分結晶系 | |
| TWI706949B (zh) | (３-胺基-環氧丙-３-基甲基)-[２-(５,５-二氧-５,６,７,９-四氫-５入*６*-硫-８-氮雜-苯并環庚烯-８-基)-６-甲基-喹唑啉-４-基]-胺之新穎晶形 | |
| JP2014074067A (ja) | メシル酸イマチニブのｆ、ｇ、ｈ、ｉおよびｋ結晶形 | |
| JP2013541592A5 (enExample) | ||
| JP2010529986A5 (enExample) | ||
| JP2008546719A (ja) | 結晶形のｏ−デスメチルベンラファキシン | |
| CN102026994A (zh) | 苯并咪唑化合物的晶体 | |
| CN105324375A (zh) | 盐酸尼洛替尼的多晶型形式 | |
| WO2011050742A1 (zh) | 阿戈美拉汀的新晶型及其制备方法 | |
| US20250177418A1 (en) | Neuroactive steroids for treatment of gastrointestinal diseases or conditions | |
| JP2012509281A5 (enExample) | ||
| WO2011140816A1 (zh) | 含腈基的噻吩并吡啶酯衍生物、其制备方法、应用和组合物 | |
| CN103068816B (zh) | 酰胺化合物的结晶 | |
| JP2018536709A5 (ja) | 脳神経の耳麻酔による疾患の治療用組成物 | |
| JP2008515907A5 (enExample) | ||
| JP2009517353A5 (enExample) | ||
| KR20150056565A (ko) | 결정질 화합물 | |
| CN1443178A (zh) | (r)－n－[5－甲基－8－(4－甲基哌嗪－1－基)－1,2,3,4－四氢－2－萘基]－4－吗啉代苯甲酰胺的新形态 | |
| WO2008080290A1 (en) | Selective m4 receptor antagonist and its medical use | |
| JP2008530225A5 (enExample) |